New cancer drug trial opens for japanese children and adults
NCT ID NCT07302347
Summary
This study is testing the safety and effectiveness of the drug pembrolizumab in Japanese children with specific solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Researchers will measure how the body processes the drug and how well it shrinks or eliminates tumors. The goal is to gather early data to see if this treatment is a viable option for these patient groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nagoya City University Hospital ( Site 0003)
RECRUITINGNagoya, Aichi-ken, 467-8602, Japan
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.